中华肝脏病杂志最新文献

{"title":"[A case of acute-on-chronic liver failure related to hepatitis B treated with tenofovir amibufenamide].","authors":"C C Zhang, T T Yuan, Q Yang","doi":"10.3760/cma.j.cn501113-20240831-00428","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240831-00428","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"50-51"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case of chronic hepatitis B with a high viral load treated with tenofovir amibufenamide].","authors":"Y N Yan, X F Yan, G X Jin, W J Deng, Y S Zheng, X Y Wang","doi":"10.3760/cma.j.cn501113-20240831-00431","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240831-00431","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"85-86"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case of hepatitis B virus-related hepatocellular carcinoma with low-level viremia achieved seronegative conversion with entecavir combined with tenofovir amibufenamide].","authors":"W G Ren, J Li, S X Zhao, L D Liu, X X Zhang, Y M Nan","doi":"10.3760/cma.j.cn501113-20240930-00516","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240930-00516","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"93-96"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Observation on the efficacy of Zhenqi Fuzheng capsule combined with tenofovir amibufenamide in the treatment of chronic hepatitis B].","authors":"Z Hua","doi":"10.3760/cma.j.cn501113-20240917-00467","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240917-00467","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the effect of Zhenqi Fuzheng capsule combined with tenofovir amibufenamide (TMF) and TMF monotherapy on the immune functions of peripheral blood lymphocytes and the inhibition of HBV replication for chronic hepatitis B (CHB). <b>Methods:</b> Seventy CHB cases were randomly divided into a treatment and a control group based on the hepatoprotective therapy, with 36 and 34 cases in the treatment and control groups, respectively. The treatment group was treated with oral tenofovir amibufenamide 25 mg once a day, in combination with Zhenqi Fuzheng capsule 1.4 g three times a day. The control group was treated with oral TMF 25 mg once a day. The treatment course was compared at 48 weeks in both groups. <b>Results:</b> Peripheral blood lymphocyte immune function indicators: The CD4⁺ cells, CD4⁺/CD8⁺ ratio, and natural killer cell values in the treatment group were higher than those in the control group at 48 weeks of treatment (<i>P</i><0.05). The treatment group had a serum HBeAg negative conversion rate of 50.0% at 48 weeks of treatment, while the control group had a rate of 26.3%. The difference between the two groups was statistically significant (<i>χ²</i>=6.98, <i>P</i><0.05). HBV DNA load: The decrease in HBV DNA load in the two groups was statistically significant compared with the baseline HBV DNA value at 24 and 48 weeks of treatment (<i>P</i><0.05). <b>Conclusion:</b> Zhenqi Fuzheng capsules combined with TMF therapy are superior for regulating immune function and reducing HBV DNA load and HBeAg-negative seroconversion rates compared to TMF alone.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"10-13"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Tenofovir amibufenamide combined with pegylated interferon α-2b in treatment of chronic hepatitis B patients with low-level viremia: a case report].","authors":"D X He, S L Ma","doi":"10.3760/cma.j.cn501113-20240824-00388","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240824-00388","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"37-40"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Tenofovir amibufenamide treatment for three cases with chronic hepatitis B].","authors":"M J Lyu, J Qiu","doi":"10.3760/cma.j.cn501113-20240903-00469","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240903-00469","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"76-78"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Tenofovir amibufenamide treatment in a case of hepatitis B virus-related decompensated liver cirrhosis].","authors":"Y P Li, G E Gou, S S Dang","doi":"10.3760/cma.j.cn501113-20240906-00481","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240906-00481","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"54-55"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case of complete viral suppression after switching to tenofovir amibufenamide treatment with chronic hepatitis B and concomitant impaired renal function].","authors":"J Li, B X Qian, Q Ye","doi":"10.3760/cma.j.cn501113-20240919-00499","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240919-00499","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"73-75"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Let's start from practical for returning academics to the clinic].","authors":"Y M Nan","doi":"10.3760/cma.j.cn501113-20241013-00536","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20241013-00536","url":null,"abstract":"<p><p>To standardize and improve the diagnosis and treatment level of chronic hepatitis B, clinical physicians should actively grasp the timing for initiating antiviral treatment, reasonably evaluate the selection of antiviral drugs, and pay close attention to the whole-process management of chronic HBV infection in their daily practice in order to reduce the risk of occurrence of serious diseases such as HCC. The concept of patient diagnosis and treatment plans should follow the treatment principles of the new version of the guidelines and formulate individualized treatment plans based on the actual situation of the patients. The development of academic activities and research should also start with solving problems found in practice or clinical needs so as to bring better diagnosis and treatment benefits to patients.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 S1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical features and genetic analysis of four cases of pediatric acute liver failure caused by <i>NBAS</i> gene variants].","authors":"J D Yu, H Zhao, Y H Fang, Y Y Luo, J G Lou, J Chen","doi":"10.3760/cma.j.cn501113-20240611-00291","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240611-00291","url":null,"abstract":"<p><p><b>Objective:</b> To analyze the clinical and genetic features of pediatric acute liver failure (PALF) caused by neuroblastoma-amplified sequence (<i>NBAS</i>) gene variants and to investigate the correlation between clinical phenotypes and genotypes. <b>Methods:</b> A retrospective analysis was conducted on the clinical data and genetic test results of 4 pediatric patients with <i>NBAS</i> gene variants presenting primarily with PALF, who were admitted to the Department of Gastroenterology at the Children's Hospital of Zhejiang University School of Medicine from August 2015 to June 2023. A literature review was performed using the keywords \"NBAS\", \"neuroblastoma amplified sequence\", \"SOPH\", \"short stature with optic nerve atrophy and Pelger-Huët anomaly\", \"liver failure\", and \"neuroblastoma amplified sequence\" in both Chinese and English, searching the CNKI, Wanfang Data Knowledge Service Platform, and PubMed databases for articles published from January 2015 to May 2024. The clinical features and genetic characteristics of domestic patients were summarized. <b>Results:</b> The age of first onset of PALF in the 4 patients ranged from 8 months to 3 years and 7 months. All patients developed PALF within 1-2 d after the onset of fever, with symptoms including vomiting, seizures, lethargy, or altered consciousness, accompanied by a sharp increase in transaminases, elevated bilirubin and blood ammonia, hyperlactatemia, and hepatomegaly. After antipyretic therapy, fluid supplementation, and other symptomatic supportive treatments, the PALF gradually improved in all patients, with 3 patients also exhibiting extrahepatic symptoms. Long-term follow-up showed that active temperature control and symptomatic management could reduce the recurrence of PALF. Genetic testing identified 8 <i>NBAS</i> gene variants sites, all confirmed as compound heterozygous mutations through family verification, including 4 missense mutations, 1 nonsense mutation, and 3 frameshift mutations. A literature review included 51 cases of domestic NBAS gene mutations, revealing that 98.0% (50/51) of patients had liver involvement, with 35 cases presenting as PALF. A total of 61 variant sites were identified, with c.3596G>A (45.1%, 23/51) being the most common hotspot mutation. <b>Conclusions:</b> <i>NBAS</i> gene mutations leading to PALF have distinct clinical and genetic characteristics, with a correlation between genotype and clinical phenotype. The c.3596G>A mutation is a hotspot variant in domestic patients and is strongly associated with the liver failure phenotype.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}